Call Us

ARTICLES

Arthrosamid®’s story started two decades ago. The brainchild of the team at Contura, the product had been in human use for various indications since 2000, and a favourable safety profile had already been established.

Unveiling the Molecular Chemistry Behind PAAG’s Lasting Presence in Arthritic Knees

Understanding Knee Osteoarthritis and the Need for Better Treatments

Knee osteoarthritis (Knee OA) is a widespread and often painful condition that affects millions of people worldwide. As the cartilage cushioning the knee joint breaks down over time, pain, stiffness, swelling, and limited movement become common symptoms—making everyday activities increasingly difficult. While treatments like painkillers, physical therapy , and steroid injections can help, their relief is usually short-lived. Surgery may be an option, but not for everyone and often comes with significant risks. One of the biggest challenges in treating Knee OA is finding therapies that remain effective inside the joint for longer periods, reducing the need for frequent retreatments.

Introducing PAAG: A Promising Solution for Long-Term Relief

Enter polyacrylamide gel, or PAAG—a synthetic gel developed to act as a shock absorber inside the knee, mimicking the cushioning of healthy cartilage. PAAG is injected directly into the joint, where it is designed to stay in place longer than many current treatments. A recent study found that PAAG helped improve knee OA symptoms over 24 months, especially in older patients with less severe joint damage. This long-lasting effect is made possible by PAAG’s unique molecular design, which helps it remain where it’s needed most. In this article, we’ll explore the chemistry behind PAAG and how it delivers sustained relief to people living with osteoarthritis.

The Science Behind PAAG: What Makes It Special

At its heart, PAAG is built from long chains of acrylamide molecules linked together to form a flexible, three-dimensional network—imagine it as a microscopic fishing net. This network holds onto water, giving PAAG its soft, gel-like texture that is both resilient and stable. A standout feature of PAAG’s molecular structure is the presence of amide groups that interact with the environment inside the knee. These connections aren’t permanent; instead, they can break and reform as the knee moves, allowing PAAG to adjust to joint activity while staying anchored. This dynamic yet stable structure is key to PAAG’s ability to remain in the joint over time.

Why PAAG Lasts in the Arthritic Knee

The environment inside an arthritic knee is complex, filled with joint fluid, proteins, and cellular debris. PAAG forms multiple types of chemical bonds with these components. Hydrogen bonds connect PAAG’s amide groups with water and proteins in the joint fluid. Electrostatic interactions—attractions between charged areas of PAAG and surrounding tissues—further help anchor the gel. Even subtle van der Waals forces, which are weak attractions between nearby molecules, contribute to its ability to stay put. Together, these interactions create a strong network that keeps PAAG from being washed away or quickly broken down. Clinical studies have shown that PAAG injections are both safe and effective, offering sustained improvement in knee function and comfort.

What This Means for Patients: Real-World Benefits and Limitations

Thanks to its robust molecular design, PAAG can continue to cushion the knee and may help reduce inflammation, providing longer-lasting relief and improved mobility compared to traditional treatments. However, PAAG isn’t a permanent solution—its results can vary based on factors such as the severity of a patient’s arthritis and individual joint conditions. Some people may still need repeat injections as time goes on. Research has shown that older patients with milder osteoarthritis, no diabetes, and issues in both knees tend to see the most benefit. Ongoing studies are working to fine-tune PAAG’s formulation and confirm its long-term safety for a wider range of patients.

The Future: Advances in Molecular Therapies for Osteoarthritis

Ultimately, PAAG’s extended effectiveness comes down to its carefully engineered chemistry, which helps it stay localized in the knee and continue working over time. This approach addresses a major challenge in osteoarthritis care, offering hope for more efficient and longer-lasting relief. As scientists deepen their understanding of PAAG and similar materials, even better treatments may be on the horizon. Innovations like PAAG are paving the way to a future where osteoarthritis patients can enjoy more active, pain-free lives.

References

Gao, H. C. K., Akhtar, M., Creedon, C., Nar, Ö. O., Verma, T., & Lee, P. Y. F. (2025). Polyacrylamide hydrogel injections in knee osteoarthritis: A PROMs-based 24 month cohort study. Journal of Clinical Orthopaedics and Trauma. https://doi.org/10.1016/j.jcot.2025.103136

Navigating ICD-10 Nuances in Primary Osteoarthritis of the Left Knee: A Clinical and Research Perspective

This article explores the importance of accurate ICD-10 coding for primary osteoarthritis of the left knee, highlighting its role in precise diagnosis, treatment planning, and research. It discusses challenges in distinguishing primary from secondary osteoarthritis, the impact of coding errors on patient care and data integrity, and the need for ongoing clinician education. Accurate coding enhances treatment effectiveness, aids fall prevention, and supports the development of personalized therapies. Advances in imaging, patient-reported outcomes, and upcoming ICD-11 updates promise improved disease tracking and management, ultimately improving patient outcomes and healthcare efficiency.

Read More »

Targeted Relief for Meniscus-Deficient Knees: How Arthrosamid® Helps Ease Post-Meniscectomy Osteoarthritis Symptoms

Arthrosamid® is a novel single-injection polyacrylamide hydrogel designed to relieve post-meniscectomy osteoarthritis knee pain by cushioning and stabilizing the joint. Unlike traditional treatments providing temporary relief, Arthrosamid® integrates into the synovial membrane, reducing bone-on-bone contact and enhancing knee function. Clinical studies show significant pain reduction and improved mobility lasting up to two years, especially in patients under 70 with moderate OA and normal BMI. The treatment is minimally invasive, well-tolerated, and may delay or prevent the need for surgery. Arthrosamid® offers a promising alternative to hyaluronic acid injections with longer-lasting effects, marking a breakthrough in managing post-meniscectomy knee osteoarthritis.

Read More »